Vipadenant (V2006) is a small molecule, adenosine A2A receptor antagonist that was being investigated in Parkinson’s disease. Due to safety concerns, development ceased in 2010 and the rights were regained from Biogen Idec in 2011 with no further investment made. In October 2014, RedoxTherapies licensed vipadenant, as it has the potential to disrupt an immunosuppressive mechanism of tumour protection, generating improved efficacy for immunotherapies of certain cancers when used in combination with other drugs. The detailed financial terms of the licence agreement with Redox are not disclosed, but Vernalis can earn income upon RedoxTherapies’ (or any sublicensee’s) achievement of milestones and royalties on successful clinical, regulatory and commercial advancement.
In June 2016, RedoxTherapies was acquired by Juno Therapeutics, subsequently acquired by Celgene Corp. Vipadenant (V2006) is currently in preclinical studies.